Clinical Trials Logo

SCCHN clinical trials

View clinical trials related to SCCHN.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04925284 Recruiting - Pancreatic Cancer Clinical Trials

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Start date: June 7, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab to subjects with advanced solid tumors.

NCT ID: NCT04107103 Recruiting - SCCHN Clinical Trials

Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma

NivoPlus
Start date: March 19, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects the combination of Nivolumab and Pemetrexed has on you and your cancer. The safety of this combination and the effectiveness of this treatment will be studied.

NCT ID: NCT03771820 Recruiting - SCCHN Clinical Trials

Combination Therapy With NC-6004 and Pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

In Phase IIa, dose-escalation study to determine the optimum tolerated dose and a recommended Phase IIb (RPIIb) dose in combination with pembrolizumab in subjects with recurrent or metastatic squamous cell carcinoma of the head and neck who have failed platinum or a platinum containing regimen. In Phase IIb, randomized control study between NC-6004 in combination with pembrolizumab versus pembrolizumab alone in the same subject population as Part 1 at the RPIIb dose identified in PIIa.

NCT ID: NCT02878655 Recruiting - SCCHN Clinical Trials

Evaluation of the Overall Quality of Life After the Neck Dissection Retro-spinal Sector (IIb), in Squamous Cell Carcinomas Clinical and Radiological N0 VADS

QDV2b
Start date: February 2015
Phase:
Study type: Observational

The nodal involvement in squamous cell carcinomas of the upper aerodigestive tract (VADS) is one of the main factors of poor prognosis, justifying the surgical management of neck dissection as a reference treatment. Under the influence of the American Hayes Martin, it was considered until the 1960s that "over the intervention was, the greater the chance of recovery was". But has since been developed by the Argentine Osvaldo Suarez the concept of functional course, which consists of resection of lymph node tissue while retaining the main structures (muscles, nerves, vessels), as opposed to the recess radical which is reserved for the invasive metastasis. In addition to these notions, our job is to evaluate the quality of life of patients with SCCHN, N0 clinical and radiological, enjoying a functional neck dissection including IIb sector to support the approach which would be to stop the systematic inclusion of this territory.